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Abstract 
INTRODUCTION: ‘Real world’ bleeding in patients exposed to different regimens of dual 
antiplatelet therapy (DAPT) and triple therapy (TT, DAPT plus an anticoagulant) have a 
clinical and economic impact but have not been previously quantified. 
METHODS AND ANALYSIS: We will use linked Clinical Practice Research Datalink 
(CPRD) and Hospital Episode Statistics (HES) data to assemble populations eligible for three 
“target trials” in patient groups: percutaneous coronary intervention (PCI); coronary artery 
bypass grafting (CABG); conservatively managed (medication only) acute coronary 
syndrome (ACS). Patients ≥18 years old will be eligible if, in CPRD records, they have: ≥1 
year of data before the index event; no prescription for DAPT or anticoagulants in the 
preceding three months; a prescription for aspirin or DAPT within two months after 
discharge from the index event. The primary outcome will be any bleeding event (CPRD or 
HES) up to 12 months after the index event. We will estimate adjusted hazard ratios for time 
to first bleeding event comparing: aspirin and clopidogrel (reference) vs. aspirin and 
prasugrel or aspirin and ticagrelor after PCI; and aspirin (reference) vs. aspirin and 
clopidogrel after CABG and ACS. We will describe rates of bleeding in patients prescribed 
triple therapy (DAPT plus an anticoagulant). Potential confounders will be identified 
systematically using literature review, semi-structured interviews with clinicians and a short 
survey of clinicians. We will conduct sensitivity analyses addressing the robustness of results 
to the study’s main limitation – that we will not be able to identify the intervention group for 
patients whose bleeding event occurs before a DAPT prescription in CPRD. 
ETHICS AND DISSEMINATION: This protocol was approved by the Independent 
Scientific Advisory Committee for the UK Medicines and Healthcare Products Regulatory 
Agency Database Research (protocol 16_126R) and the South West Cornwall and Plymouth 
Research Ethics Committee (17/SW/0092). The findings will be presented in peer-reviewed 
journals, lay summaries, and briefing papers to commissioners/other stakeholders. 
ISRCTN: 76607611
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Strengths and limitations of this study 
 We designed our study using the framework recommended by the Cochrane Bias and 
Non-Randomized Studies Methods Groups for establishing appropriate patient 
populations, interventions and follow-up to emulate three hypothetical RCTs (target 
trials). 
 We will identify potential confounders systematically using literature review, semi-
structured interviews with clinicians (cardiologists, cardiac surgeons and general 
practitioners) and a short survey with an additional group of clinicians. 
 Because there are no medication data in HES, we will assume that patients’ first 
DAPT prescription that appears in CPRD after their hospital admission is what they 
were prescribed at discharge.  
 We will conduct sensitivity analyses to address the robustness of results to different 
assumptions about the unknown intervention group in patients who died or had a 
bleeding event before a DAPT prescription in CPRD.  
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Introduction 
Dual antiplatelet therapy (DAPT), a combination of aspirin and either clopidogrel, prasugrel, 
or ticagrelor, is recommended for secondary prevention of ischaemic events (heart attack and 
stroke) in people with coronary artery disease. Guidelines recommend that patients are 
treated with DAPT for 6 to 12 months following myocardial infarction (MI) and coronary 
interventions (percutaneous coronary intervention, PCI, and coronary artery bypass grafting, 
CABG) [1-3] and support the use of the more potent antiplatelet inhibitors ticagrelor and 
prasugrel [2]. Antiplatelet agents reduce the risk of ischaemic events, by preventing the 
formation of clots in atherosclerotic coronary arteries and within stents (following PCI) or 
grafts (following CABG), but increase the risk of bleeding [4]. Randomized controlled trials 
(RCTs) have shown that adding clopidogrel to aspirin leads to 1% excess risk of major 
bleeding (requiring admission to hospital) compared with aspirin alone [5, 6]. Prasugrel and 
ticagrelor reduce the risk of ischemic events further but also further increase the risk of 
bleeding [7].  Some patients (e.g. those with existing atrial fibrillation or those who develop 
atrial fibrillation after PCI, CABG or ACS) are prescribed an anticoagulant (e.g. warfarin, 
dabigatran, rivaroxaban, apixaban) in addition to DAPT (triple therapy, TT), which further 
increases the risk of bleeding.  
 
“Real world” bleeding events that do not require any intervention are likely to be much more 
frequent than those reported in RCTs, which excluded patients at high risk of bleeding and 
mainly reported only on major bleeding. Bleeding events that do not result in hospitalisation 
are largely managed in primary care and may have a significant clinical and economic impact 
[8]. Minor and nuisance bleeding (nose and gum bleeds, bruising and prolonged bleeding 
from cuts) may also reduce adherence to DAPT and therefore the benefit of DAPT in non-
adherent patients [9] who are at increased risk of a secondary ischaemic coronary episode 
[10].  Only three studies have reported the incidence and consequences of nuisance bleeding 
after DAPT [11-13]; these suggest that nuisance bleeding is common (affecting 29-38% of 
patients) and impacts on adherence (11% of patients in one study discontinued clopidogrel 
[12]). A nested case control study using the Health Improvement Network (a UK primary 
care database) reported an increased risk of upper gastrointestinal bleeding with clopidogrel 
and aspirin compared with aspirin alone (relative risk [RR], 2.08; 95% confidence interval 
[CI], 1.34 to 3.21) [14].  
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The economic impact of bleeding events associated with DAPT is also poorly characterized, 
in particular for minor bleeding events and their impact on health-related quality of life 
[8].This is not surprising given that health economic analyses often lack detailed data on 
adverse effects of interventions, despite consensus that such effects should be considered [15, 
16]. To ensure appropriate decisions are made about which DAPT regimens to use in clinical 
practice, the health and resource use consequences of minor and major bleeding events 
should be incorporated into assessments of cost-effectiveness. For DAPT, this entails 
accounting for uncertainty in the absolute risk of bleeding, the impact of different bleeding 
events on health-related quality of life and treatment adherence and subsequent risk of 
secondary ischaemic events, and the cost implications of managing these bleeding events.   
 
We propose to use Hospital Episode Statistics (HES) and the Clinical Practice Research 
Datalink (CPRD) databases to estimate the incidence of all bleeding events occurring in 
patients prescribed different DAPT or TT regimens after undergoing coronary interventions 
(PCI and CABG) and in conservatively-managed ACS patients. Our study will also provide 
parameter estimates to update existing cost effectiveness models. We will use the framework 
recommended by the Cochrane Bias and Non-Randomized Studies Methods Groups for 
establishing appropriate patient populations, interventions and follow-up to emulate the 
following three hypothetical RCTs (hereafter referred to as the target trials, Table 1) [17]: 
1. In patients who have undergone PCI, estimate the effect on bleeding events of 
assignment to aspirin and clopidogrel (reference) versus aspirin and prasugrel or 
aspirin and ticagrelor. 
2. In patients who have undergone CABG, estimate the effect on bleeding events of 
assignment to aspirin (reference) versus aspirin and clopidogrel. 
3. In patients who are conservatively-managed patients after presenting with ACS, 
estimate the effect on bleeding events of assignment to aspirin (reference) versus 
aspirin and clopidogrel.
 7 
Methods 
Data sources 
CPRD is a database of primary care electronic health record data (available online via CPRD 
GOLD) from participating general practices, covering 7% of the UK population [18]. Patients 
included in CPRD are largely representative of the UK population in terms of age, sex, 
ethnicity, and body mass index. HES covers all hospital admissions for all English patients 
whose treatment is funded by the UK National Health Service (NHS), whether treated by the 
NHS or by independent providers [19]. Seventy-five percent of English general practices 
included in CPRD are linked to HES data [18]. We obtained data from 1 April 2009 to 31 
July 2017; this period covers the introduction of the newer antiplatelet agents prasugrel and 
ticagrelor. This study protocol has been approved by the Independent Scientific Advisory 
Committee (ISAC) of the CPRD (protocol number 16_126R). 
 
Study populations 
Eligibility and exclusion criteria for the three target trials (for patients undergoing PCI, 
patients undergoing CABG; or patients hospitalised and conservatively-managed for ACS) 
are listed in Table 1. We will identify eligible patients who are included in CPRD and 
eligible for linkage with HES and Office for National Statistics (ONS) mortality data 
(because they have a valid NHS number and are registered at a practice that was participating 
in the linkage programme). Patients are included if they had a PCI, CABG or ACS (index 
event) a record in HES during the study period (1 April 2010 – 1 January 2017), and have at 
least 1 year of linked CPRD-HES data before the date of their index event. They must also 
have been prescribed one of the treatment regimens being compared in the target trial 
corresponding to their index event. One year’s data preceding eligibility for the target trial is 
adequate to apply most of the exclusion criteria and determine co-morbidities and medication 
history: such information would be collected at baseline in a randomized trial. The following 
Office of Population Censuses and Surveys (OPCS) procedure codes (PCI and CABG) and 
International Classification of Diseases (ICD-10) codes (ACS no procedure) will be used to 
identify patients: PCI, K49, K50 & K75; CABG, K40, K41, K42, K43, K44, K45 & K46; 
ACS without a procedure, I20.0, I21, I22, I24.9 (with no OPCS code for PCI or CABG in the 
same hospital admission). Figure 1 shows full details of the inclusion and exclusion criteria. 
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Table 1. Summary of three target trials and how observational data will be used to emulate these 
PICO component Target trial Issues in emulating the target trial using observational 
data 
Eligibility criteria Target trial 1 (PCI) 
Consecutive patients (age ≥18 years) undergoing PCI (emergency or 
elective). Exclusions: DAPT or anticoagulant use in the previous 3 
months; major bleed requiring hospitalization in previous 12 months; 
renal failure requiring dialysis; intolerance/allergy to aspirin, 
clopidogrel, prasugrel or ticagrelor. 
Target trial 2 (CABG) 
Consecutive patients (age ≥18 years) undergoing CABG (urgent and 
elective). Exclusions: DAPT or anticoagulant use in the previous 3 
months; other concomitant cardiac surgery (e.g. valve surgery); major 
bleed requiring hospitalization in previous 12 months; renal failure 
requiring dialysis; intolerance/allergy to aspirin, clopidogrel, prasugrel 
or ticagrelor. 
Target trial 3 (conservatively-managed ACS) 
Consecutive patients (age ≥18 years) hospitalized for an acute coronary 
syndrome (ACS): myocardial infarction (MI) with or without ST-
elevation or unstable angina. Exclusions: PCI or CABG performed at 
time of ACS diagnosis; major bleed requiring hospitalization in 
previous 12 months; renal failure requiring dialysis; intolerance/allergy 
to aspirin, clopidogrel, prasugrel or ticagrelor. 
CPRD-HES linked dataset contains information that allows 
us to identify all eligible patients for the three target trials. 
The study period is April 2009-July 2017. All eligible 
patients will have sufficient data (1 year) preceding their 
index event to apply the exclusion criteria and characterize 
the population (e.g. co-morbidities) and sufficient follow-
up data (1 year) to identify outcomes. It is not possible to 
capture intolerance/allergy to aspirin, clopidogrel, 
prasugrel or ticagrelor. 
Interventions 
 
Target trial 1 (PCI) 
Clopidogrel (75mg daily) or prasugrel (5mg or 10mg daily) or 
ticagrelor (90mg twice daily). All patients will receive aspirin (at a 
dose of 75mg daily, in line with current guidelines).  
Target trial 2 (CABG)  
Clopidogrel (75mg) in addition to aspirin (at a dose of 75mg daily, in 
Relevant interventions can be identified as CPRD has 
information on all medications (including doses) prescribed 
in primary care.  
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line with current guidelines) or aspirin only (any dose, reflecting 
variation in usual care). 
Target trial 3 (conservatively-managed ACS) 
As for target trial 2. 
Assignment to 
interventions  
Participants are assigned to DAPT interventions in hospital. Participants enter the study at index procedure date for PCI 
and CABG, and episode start date for ACS, and will be 
assigned to DAPT interventions using first prescription in 
CPRD (within 2 months of hospitalization) as a proxy for 
what they were prescribed in hospital (there are no 
medications data in HES). This assignment will exclude a 
proportion of eligible patients (those who died or 
experienced a major bleed that caused them to stop DAPT, 
or patients who have no prescription for DAPT within the 2 
month window); we will identify and describe the 
characteristics of these excluded patients.  
In sensitivity analyses, we will address the robustness of 
results to different assumptions about the intervention 
group in those patients where the DAPT medication is 
unknown or a major bleed occurs prior to the first DAPT 
medication, by using multiple imputation models for 
handling missing data. Prior known information regarding 
the likely prescription based on patient characteristics or 
general policies will be incorporated in these analyses. 
Follow-up Starts at assignment to intervention and ends at first bleed or 12 
months from assignment (whichever comes first). 
Starts at time of hospitalization for PCI, CABG or ACS 
and ends at first bleed or 12 months from hospitalization 
(whichever comes first). 
Primary outcome Any bleed within 12 months of the start of DAPT (DAPT is prescribed 
at hospitalization for PCI, CABG or ACS). 
Any bleed within 12 months of hospitalization for PCI, 
CABG or ACS.  
Analysis Intention to treat According to first prescription for DAPT in CPRD 
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Interventions 
The interventions of interest for the three target trials are shown in Table 1. Guidelines 
recommend low dose aspirin (75 to 100mg/d) plus either clopidogrel (75mg/d), prasugrel 
(5mg/d or 10mg/d), or ticagrelor (90mg twice/d) for PCI and conservatively-managed ACS 
patients. For PCI patients, the interventions of interest are aspirin and clopidogrel, aspirin and 
prasugrel, and aspirin and ticagrelor. In conservatively-managed ACS patients, clopidogrel is 
the most commonly prescribed second antiplatelet agent (in addition to aspirin) and a large 
proportion of patients are prescribed aspirin only, therefore the interventions of interest are 
aspirin only (75 to 100mg/d) and aspirin and clopidogrel. There is variation in aspirin 
prescription for CABG patients; some surgeons choose 75mg/d, others 150mg/d, or 300mg/d. 
surgeons may also prescribe an additional antiplatelet agent, most commonly clopidogrel. 
Therefore, the comparisons of interest in CABG patients are aspirin only (any dose, reflecting 
variations in usual care in different hospitals) and aspirin and clopidogrel (doses as for PCI). 
We have specified these comparisons based on preliminary feasibility counts from CPRD, 
which indicate that few CABG and conservatively-managed ACS patients are prescribed 
aspirin and prasugrel or aspirin and ticagrelor. 
 
In the target trials the interventions would be assigned during the hospital stay, as soon as 
patients are eligible for antiplatelet therapy. Our observational dataset does not have 
information on medication given to patients at discharge, because HES does not include 
medications data. Therefore, the first time at which we have information on the antiplatelet 
regimen to which patients were assigned in hospital is when they receive their first primary 
care prescription/s for aspirin or DAPT, recorded in CPRD. It is reasonable to use these as a 
proxy for the medications that patients started in hospital, because patients’ general 
practitioners are unlikely to change the prescriptions that were started in hospital.  
 
We will classify patients according to the first prescription recorded in CPRD during the first 
two months after hospitalization for PCI, CABG, or ACS. This two-month window is based 
on variability in the amount of DAPT medication provided to patients in hospital following 
their PCI, CABG or ACS and hence variability in the time when they first request a repeat 
prescription from their general practice. A preliminary investigation showed that more than 
80% of eligible patients have a prescription for one or more antiplatelet agents during this 
time period. If a patient only has a prescription for aspirin during the 2-month window after 
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hospital discharge, they will be assigned to an aspirin only intervention. If patients also 
receives a prescription for clopidogrel, prasugrel or ticagrelor, they will be assigned to 
aspirin/clopidogrel, aspirin/prasugrel or aspirin/ticagrelor. If there is a prescription for more 
than one additional antiplatelet agent in the 2-month window, we will assign the patient to an 
intervention based on the agent prescribed first. For example, if a patient has an aspirin 
prescription and a prescription for clopidogrel before a prescription for ticagrelor, the patient 
will be assigned to the aspirin/clopidogrel intervention. Patients with no prescriptions in 
CPRD for aspirin, or aspirin and clopidogrel, prasugrel or ticagrelor within the 2-month 
window will be excluded from the main analysis. We will conduct sensitivity analyses of all 
eligible patients including those with unknown DAPT regimens or a major bleed prior to first 
DAPT prescription, by estimating assignment to DAPT interventions for those with no 
prescription data using multiple imputation based on a range of assumptions [20]. 
 
Outcomes  
The primary outcome will be any bleeding event, classified as type 2-5 by the Bleeding 
Academic Research Consortium (BARC) bleeding scale [21]. For each patient, we will 
identify all bleeding events in HES and CPRD  during follow-up. We will not be able to 
identify BARC type 1 bleeding events (bleeding that is not actionable and does not cause the 
patient to seek treatment) as type 1 assumes there is no interaction with the health system or 
healthcare professionals therefore no bleed event will be recorded in HES or CPRD.  We 
have specified a comprehensive list of bleeding codes in CPRD and HES (see Appendix 1). 
These will be categorised according to anatomical site for descriptive purposes. Secondary 
outcomes will be: any major bleeding event; any minor bleeding event; all-cause mortality; 
cardiovascular mortality; mortality from bleeding (these will be identified from linked ONS 
data); hospital admission for a bleeding event (inpatient HES); MI; stroke; additional 
coronary intervention. 
 
Follow up 
The start of follow up (the index event) will be the date of the index hospital procedure (PCI, 
CABG) or start date of the hospital episode that contains the ACS diagnosis (ACS).  Patients 
will be followed up until 12 months after the index event, since DAPT is prescribed for 12 
months in accordance to guidelines. 
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Confounding and co-interventions 
Potential confounders (variables that predict both risk of bleeding and intervention group) 
will be specified a priori [22, 23].  We will identify confounders and co-interventions using 
literature review and clinician expertise as recommended by the Cochrane Bias and Non-
Randomized Studies Methods Groups [17]. We will carry out a comprehensive and 
systematic literature search to identify all RCT and cohort studies of DAPT interventions, or 
cohort studies that identify predictors of bleeding. The literature searches for the review are 
included in Appendix 2. Abstracts will be screened by one researcher and full text papers 
will be obtained. Data on confounders and co-interventions will be extracted by two 
researchers independently using a data extraction form specifically designed for the study; 
variables extracted will include study characteristics, population characteristics (reported in 
the tables of baseline characteristics), factors adjusted for in the statistical analyses, and 
factors reported to predict risk of bleeding in our populations.  We will not perform a risk of 
bias assessment because the aim of the review is only descriptive (i.e. the output will be lists 
of confounders and co-interventions) and there are no established criteria for assessing the 
validity with which primary researchers consider potential confounders and co-interventions; 
therefore it would be inappropriate to apply a risk-of-bias tool for studies estimating a 
treatment effect. We will use “saturation” as a criterion for discontinuing data collection, 
defined as review of 10 consecutive studies without identifying an additional confounder/co-
intervention. 
 
In parallel, we will conduct semi quantitative interviews with six clinicians in each of three 
groups: cardiologists; cardiac surgeons and general practitioners (GPs, to determine whether 
DAPT prescriptions are changed in primary care). The main aim of the clinician interviews is 
to understand DAPT prescribing practice in the UK and identify the factors (relating to 
patients, centres and prescribing practices of the individual doctors) that influence the 
decision about which antiplatelet regimen to prescribe. All factors that influence DAPT 
prescribing (confounders) identified from the literature review and clinician interviews will 
be combined in a short survey (SurveyMonkey). The survey questionnaire will be 
administered online to all consultant members of the British Cardiovascular Society 
(cardiologists) andthe Society for Cardiothoracic Surgery (cardiac surgeons).  The survey will 
be either emailed to all members individually (if the professional bodies agree) or advertised 
in weekly/monthly newsletters. Confounders will be grouped in confounding domains [17]. 
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We will attempt to identify each potential confounder (identified through the literature 
review, clinician interviews and survey) in the CPRD or HES dataset but acknowledge that 
there may be missing data across patients (and time) for some confounders.  
 
Sample size  
Estimated rates of bleeding with the different therapies are 5% for aspirin, 9% for 
aspirin/clopidogrel, and 12% for aspirin/prasugrel and aspirin/ticagrelor [5, 6, 24, 25]. 
Preliminary feasibility counts provided by CPRD suggest that there will at least the following 
numbers of patients eligible for each target trial:  
 PCI: aspirin/clopidogrel (reference, 6738 patients) vs aspirin/prasugrel (842 patients) 
or aspirin/ticagrelor (770 patients) 
 CABG: aspirin (reference, 2556 patients) vs aspirin/clopidogrel (595 patients) 
 Conservatively-managed ACS: aspirin (reference, 8148 patients) vs 
aspirin/clopidogrel (3082 patients) 
These estimates give expected event rates of at least 700 for PCI, 180 for CABG and 680 for 
ACS, assuming a ratio of 8:1 (aspirin/clopidogrel:aspirin/prasugrel or 
aspirin/clopidogrel:aspirin/ticagrelor) for PCI, 4:1 (aspirin:aspirin/clopidogrel) for CABG and 
2.5:1 (aspirin:aspirin/clopidogrel) for ACS. The hazard ratios detectable with 90% and 80% 
power at the 5% statistical significance, assuming the group ratios given above are shown in 
Table 2. The correlation of the DAPT with other covariates adjusted for is unknown and we 
assessed the impact of a range of correlations (0, 0.3 and 0.5). 
 
Table 2. Hazard ratios for a range of correlations for PCI, CABG and ACS 
Ratio of presence: 
absence of covariate 
Squared correlation 
with other covariates 
Hazard ratio detectable 
90% power     80% power 
PCI   
8:1 0 (i.e. unadjusted) 1.48 1.41 
 0.3 1.60 1.50 
 0.5 1.74 1.62 
CABG    
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4:1 0 (i.e. unadjusted) 1.83 1.69 
 0.3 2.06 1.87 
 0.5 2.35 2.10 
Conservatively-
managed ACS 
   
2.5:1 0 (i.e. unadjusted) 1.32 1.27 
 0.3 1.39 1.33 
 0.5 1.48 1.40 
 
 
Statistical analyses 
We will describe temporal changes in DAPT prescribing and bleeding for PCI, CABG and 
ACS populations. We will use descriptive statistics to summarize the characteristics of the 
different intervention groups and standardised mean differences to compare them.  We will 
estimate rates of bleeding (number of events/person time) with 95% confidence intervals 
(CIs) for each group.  We will separate major and minor bleeding since adverse events of 
each type have different health and resource use consequences. 
 
Analyses will estimate the effects of assigned intervention (analogous to an intention-to-treat 
analysis of a randomized trial) for the antiplatelet regimens corresponding to the first 
prescription of aspirin or DAPT in CPRD (see Interventions). We will use parametric 
survival models to estimate adjusted hazard ratios (HRs) with 95% CIs for the time to first 
bleeding event, comparing intervention groups for each target trial. Exploratory analyses, 
including assessment of proportional hazards assumptions, will be used to inform the choice 
of survival distribution (e.g. Weibull). Estimated time-dependent event probabilities will be 
used to update existing cost-effectiveness models [26]. The confounding factors to be 
included in the model (which will be  identified as described previously and grouped into 
confounding domains from our dataset), the modelling strategy and the approach to handling 
correlated covariates will be documented in a data analysis plan. Participants free from a 
bleeding event will be censored at 12 months after the index event. For secondary endpoints 
we will use survival models to estimate adjusted hazard ratios (HRs) with 95% CIs for time 
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to first event. For mortality outcomes, we will take account of the competing risks of death 
due to other causes. 
 
We will perform three sets of sensitivity analyses: 
1. We will address the unknown intervention group of eligible patients who have no 
prescription data and therefore cannot be assigned to an intervention (i.e. those that died 
before receiving their first prescription, had a major bleed which caused them to stop 
DAPT, or have no aspirin/DAPT prescription recorded in CPRD within the 2 month 
window). These analyses will be undertaken using multiple imputation methods to deal 
with missing information on DAPT medication and will take patient characteristics, 
procedure/diagnosis and general medication policies into account, using a range of 
assumptions. 
2. We will address the possibility that some minor bleeding events are not documented in 
CPRD but nevertheless prompt medication changes. We anticipate that most bleeding 
events will occur soon after the index event and before any medication change.  
Medication changes will be described relative to bleeding events observed (e.g. before 
event, after event, no bleeding event observed). If a substantial proportion (>10%) of 
people change medication before their first bleeding event, we will perform a sensitivity 
analysis excluding these patients. 
3. We will assess the sensitivity of our findings when the analysis is restricted to a sub-
population of patients at low risk of bleeding (i.e. excluding people at high risk for 
bleeding) who, we hypothesise, have the lowest risk of residual confounding. 
 
We will attempt to identify an instrumental variable (e.g. clinician/GP practice prescribing 
practice) to control for confounding by indication.  If we are successful we will repeat the 
above analyses for the PCI, CABG and ACS populations.  
 
We will explore the consistency of treatment effect estimates in the following subgroups: 
ACS vs non-ACS (PCI and CABG populations); diabetic vs non-diabetic; chronic kidney 
disease vs. non-chronic kidney disease; concurrent prescription for proton pump inhibitors vs. 
no prescription for proton pump inhibitors. All subgroups will be defined in the data analysis 
plan and chosen based on the characteristics of the analysis populations before carrying out 
any analyses by intervention group.  We will report p values from tests of interaction. 
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Triple therapy (TT) 
We will establish additional groups of patients (PCI or CABG or conservatively-managed 
ACS) based on triple therapy (TT) prescription. The main reason for prescribing an 
anticoagulant is to treat atrial fibrillation in a patient otherwise eligible for either of the three 
target trials. Atrial fibrillation can precede (long-term anticoagulation for pre-existing atrial 
fibrillation) or follow the index event (anticoagulation for new-onset atrial fibrillation). 
Figure 2 shows how the patient groups receiving TT will be constructed. 
 
We will identify patients on long-term anticoagulation by identifying prescriptions of oral 
anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban) in the 3 months before their 
index event and a concomitant prescription of any anticoagulant (TT) with DAPT and in the 
first two months after the index admission. Patients who develop atrial fibrillation after the 
index event will be identified from any new anticoagulant prescription during follow-up. We 
have compiled a list of all drug codes in CPRD for antiplatelet agents (aspirin, clopidogrel, 
prasugrel and ticagrelor) and anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban) 
(see Appendix 3).  
  
In patients receiving various TT regimens (grouped by pre-index event anticoagulant 
prescription and post-index event anticoagulant prescription in PCI, CABG and ACS 
separately, see Figure 2), we will describe rates of bleeding (number of events/person time) 
with 95% CIs for each group. We have not specified comparison groups because we know 
there is large variation in prescribing of anticoagulants;TT is usually prescribed for a 
relatively short period of time (1-6 months, depending on a patient’s individual risks of 
thrombosis and bleeding) after which an antiplatelet agent (usually aspirin) is removed and 
patients continue to receive an anticoagulant and single antiplatelet for the remainder of the 
12 months after the index admission.  
 
Patient and public involvement 
We set up a patient advisory group comprising of patients from our three cohorts (PCI, 
CABG and conservatively-managed ACS). The group was consulted about several aspects of 
the proposed study. Group members confirmed the importance of the research topic and and 
agreed that the choice of antiplatelet regimen should be based on shared decision making, 
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with clinicians and patients weighing the potential benefits against the adverse side effects 
and practical inconvenience. Our PPI group will attend regular meetings to discuss results 
from the study and will also contribute and collaborate on the development of our results 
dissemination strategy. 
 
Ethics and dissemination 
This study protocol has approval from the Independent Scientific Advisory Committee for the 
UK Medicines and Healthcare products Regulatory Agency Database Research (protocol 
16_126R). We also obtained ethical approval for the semi-structured interviews with 
clinicians and survey from South West Cornwall and Plymouth Research Ethics Committee, 
17/SW/0092. The findings will be presented at national/international conferences, published 
in peer-reviewed academic journals and accessible formats in newsletters to patients (where 
available).  The findings will also be reported as a briefing paper to commissioners (e.g. 
commissioning groups, National Institute for Health and Care Excellence, NICE) and to other 
health care stakeholders with an interest in the research through the Cardiac & Stroke 
Networks.  We will also present and discuss our results at local CPRD working groups to 
disseminate out methods to other researchers using the CPRD database.  
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Figure 1. Study diagram describing the construction of the PCI, CABG and ACS 
(conservatively managed) populations. 
 
Figure 2. Study diagram describing the construction of the triple therapy (TT) populations. 
 
 
 
 
 
 
